Renovaro (RENB) Competitors $0.71 -0.04 (-5.73%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RENB vs. KURA, TECX, CRGX, HUMA, ANNX, PHVS, KROS, MREO, RAPP, and DNAShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Kura Oncology (KURA), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), Humacyte (HUMA), Annexon (ANNX), Pharvaris (PHVS), Keros Therapeutics (KROS), Mereo BioPharma Group (MREO), Rapport Therapeutics (RAPP), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Kura Oncology Tectonic Therapeutic CARGO Therapeutics Humacyte Annexon Pharvaris Keros Therapeutics Mereo BioPharma Group Rapport Therapeutics Ginkgo Bioworks Kura Oncology (NASDAQ:KURA) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking. Does the MarketBeat Community prefer KURA or RENB? Kura Oncology received 425 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformKura OncologyOutperform Votes42569.44% Underperform Votes18730.56% RenovaroN/AN/A Which has higher earnings and valuation, KURA or RENB? Kura Oncology is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura OncologyN/AN/A-$152.63M-$2.36-3.08RenovaroN/AN/A-$80.65M-$0.96-0.74 Which has more volatility & risk, KURA or RENB? Kura Oncology has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Does the media favor KURA or RENB? In the previous week, Kura Oncology had 2 more articles in the media than Renovaro. MarketBeat recorded 3 mentions for Kura Oncology and 1 mentions for Renovaro. Kura Oncology's average media sentiment score of 1.00 beat Renovaro's score of 0.47 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Renovaro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KURA or RENB? Kura Oncology currently has a consensus target price of $27.38, suggesting a potential upside of 277.07%. Given Kura Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Kura Oncology is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in KURA or RENB? 71.4% of Renovaro shares are held by institutional investors. 5.5% of Kura Oncology shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is KURA or RENB more profitable? Kura Oncology's return on equity of -44.09% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -44.09% -39.57% Renovaro N/A -67.54%-52.89% SummaryKura Oncology beats Renovaro on 10 of the 15 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.21M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.749.2687.2517.09Price / SalesN/A309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / Book0.796.055.314.79Net Income-$80.65M$154.90M$122.54M$224.99M7 Day Performance-13.37%1.35%1.44%2.37%1 Month Performance-56.89%0.41%2.51%4.40%1 Year Performance-85.18%3.08%25.32%20.10% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro0.7747 of 5 stars$0.71-5.7%N/A-85.2%$112.21MN/A-0.7420KURAKura Oncology4.3093 of 5 stars$7.24-1.1%$27.38+278.1%-50.6%$563.01MN/A-3.07130TECXTectonic Therapeutic2.9077 of 5 stars$37.83-5.8%$72.25+91.0%N/A$558.11MN/A-6.42120Positive NewsCRGXCARGO Therapeutics1.6006 of 5 stars$12.04-10.8%$31.80+164.1%-40.4%$554.18MN/A-2.83116Positive NewsGap DownHUMAHumacyte2.8971 of 5 stars$4.39-4.8%$13.71+212.4%+65.2%$552.52M$1.57M-3.28150ANNXAnnexon2.2269 of 5 stars$4.94+2.3%$15.80+219.8%-3.2%$526.57MN/A-4.7060PHVSPharvaris2.5542 of 5 stars$16.41-7.8%$39.25+139.2%-32.7%$522.49MN/A-5.8630High Trading VolumeKROSKeros Therapeutics3.2175 of 5 stars$12.82-12.0%$75.00+485.0%-79.5%$519.30M$651,000.00-2.46100Gap UpHigh Trading VolumeMREOMereo BioPharma Group2.238 of 5 stars$3.34-5.9%$7.83+134.5%-9.4%$518.19M$1M0.0040High Trading VolumeRAPPRapport Therapeutics2.0976 of 5 stars$13.97-5.7%$35.00+150.5%N/A$510.97MN/A0.00N/ADNAGinkgo Bioworks0.6198 of 5 stars$8.83-9.7%$4.58-48.2%N/A$507.54M$217.11M-0.681,218 Related Companies and Tools Related Companies Kura Oncology Alternatives Tectonic Therapeutic Alternatives CARGO Therapeutics Alternatives Humacyte Alternatives Annexon Alternatives Pharvaris Alternatives Keros Therapeutics Alternatives Mereo BioPharma Group Alternatives Rapport Therapeutics Alternatives Ginkgo Bioworks Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RENB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
